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Abstract

Background and objectives Cognitive impairment is a core symptom domain of schizophrenia, neurological
disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive
functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia
provide limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a
component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability
to improve cognitive impairment has not been thoroughly explored. The aim of this systematic review was to
evaluate preclinical and clinical literature on the effects of CBD in cognitive domains relevant to
schizophrenia. Methods A systematic literature search was performed across numerous electronic databases
for English language articles ( January 1990-March 2016), with 27 articles (18 preclinical and 9 clinical
studies) included in the present review. Results CBD improves cognition in multiple preclinical models of
cognitive impairment, including models of neuropsychiatric (schizophrenia), neurodegenerative (Alzheimer's
disease), neuro-inflammatory (meningitis, sepsis and cerebral malaria) and neurological disorders (hepatic
encephalopathy and brain ischemia). To date, there is one clinical investigation into the effects of CBD on
cognition in schizophrenia patients, with negative results for the Stroop test. CBD attenuates Δ9-THCinduced cognitive deficits. Conclusions The efficacy of CBD to improve cognition in schizophrenia cannot be
elucidated due to lack of clinical evidence; however, given the ability of CBD to restore cognition in multiple
studies of impairment, further investigation into its efficacy in schizophrenia is warranted. Potential
mechanisms underlying the efficacy of CBD to improve cognition are discussed.
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31

Abstract

32

Background and Objectives: Cognitive impairment is a core symptom domain of schizophrenia, neurological

33

disorders and substance abuse. It is characterised by deficits in learning, memory, attention and executive

34

functioning and can severely impact daily living. Antipsychotic drugs prescribed to treat schizophrenia provide

35

limited cognitive benefits and novel therapeutic targets are required. Cannabidiol (CBD), a component of the

36

cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve

37

cognitive impairment has not been thoroughly explored. The aim of this systematic review was to evaluate

38

preclinical and clinical literature on the effects of CBD in cognitive domains relevant to schizophrenia.

39

Methods: A systematic literature search was performed across numerous electronic databases for English

40

language articles (January 1990 to March 2016), with 27 articles (18 preclinical and 9 clinical studies) included

41

in the present review.

42

Results: CBD improves cognition in multiple preclinical models of cognitive impairment, including models of

43

neuropsychiatric (schizophrenia), neurodegenerative (Alzheimer’s disease), neuro-inflammatory (meningitis,

44

sepsis and cerebral malaria) and neurological disorders (hepatic encephalopathy and brain ischemia). To-date,

45

there is one clinical investigation into the effects of CBD on cognition in schizophrenia patients, with negative

46

results for the stroop test. CBD attenuates Δ9-THC-induced cognitive deficits.

47

Conclusions: The efficacy of CBD to improve cognition in schizophrenia cannot be elucidated due to lack of

48

clinical evidence; however, given the ability of CBD to restore cognition in multiple studies of impairment,

49

further investigation into its efficacy in schizophrenia is warranted. Potential mechanisms underlying the

50

efficacy of CBD to improve cognition are discussed.

51
52
53
54
55
56
57
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2

61

1 Introduction

62

Since the introduction of ‘third generation’ atypical antipsychotics in the 1990s, there have been relatively few

63

clinically significant advances in treatment options for patients suffering from affective and non-affective

64

psychotic disorders such as schizophrenia and bipolar disorder [1]. Antipsychotics have therapeutic efficacy in

65

treating some of the positive (hallucinations, delusions) and negative (anhedonia, apathy) symptoms of

66

schizophrenia; however, they are limited in their ability to treat the cognitive domain of the disease [2].

67

Cognitive impairment is a core symptom underlying many neuropsychiatric disorders. Approximately 75-85%

68

of people with schizophrenia experience deficits in cognition that negatively impact day-to-day living, including

69

the ability to maintain employment, relationships and self-care [3]. Cognitive deficits often precede the

70

emergence of other symptoms in schizophrenia, are associated with poor medication compliance and a higher

71

tendency for relapse in first episode psychosis [4]. In fact, cognitive deficits are considered a better prognostic

72

indicator in schizophrenia patients than other symptom domains because the severity of cognitive dysfunction

73

correlates with earlier disease onset [2] and can predict clinical course and future functional outcomes [5]. As

74

current antipsychotic medications show minimal benefits for cognitive impairment [2] and have adverse side-

75

effects (such as weight gain and motor disturbances) [6], there is an urgent requirement to identify new

76

pharmacological treatments that can enhance cognitive function and improve the overall quality of life for

77

people with schizophrenia. In an effort to address cognitive dysfunction in schizophrenia, the Measurement and

78

Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was developed that identifies

79

7 primary cognitive domains as targets for treatment in schizophrenia [2]. These domains include processing

80

speed, verbal learning and memory, attention and vigilance, reasoning and problem solving, visual learning and

81

memory, social cognition and working memory [2]. The authors [2] recommend that preclinical studies

82

assessing the efficacy and functional outcomes of new pharmacological treatments in schizophrenia models

83

should use behavioural tests that examine domains identified in MATRICS. Likewise, the MATRICS

84

Consensus Cognitive Battery (a battery of 10 tests that examine the MATRICs cognitive domains) should be

85

used in clinical trials that assess the efficacy of potential cognitive-enhancing drugs for schizophrenia, to ensure

86

standardised testing and maximise reproducibility between trials [2].

87
88

Cannabis sativa is the most widely used drug in the world and contains over 70 different constituents, including

89

delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) [7]. Compared to the general population,

90

individuals with schizophrenia are twice as likely to consume cannabis, with evidence of worsened psychotic
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91

symptoms and a higher incidence of relapse and poor treatment outcomes in users [7]. Cannabis use during

92

adolescence is a well-documented risk factor for developing schizophrenia and lowers the age of symptom onset

93

[8]. Cannabis interacts with the endogenous cannabinoid system and alterations in endogenous cannabinoid

94

signalling have been observed in patients with schizophrenia. For example, studies report elevated levels of the

95

endogenous cannabinoids anandamide (AEA) and 2-arachidonyl glycerol (2-AG) in cerebrospinal fluid and

96

blood samples of patients [9-13], while post-mortem brain tissue and neuroimaging studies report elevations in

97

cannabinoid CB1 receptor density in brain regions implicated in cognition, in people with schizophrenia [14-

98

16]. Interestingly, ∆9-THC administration induces symptoms in healthy volunteers that resemble psychosis,

99

including hallucinations, delusions, depersonalisation and emotional lability, coupled with cognitive impairment

100

in learning and memory domains [7]. On the other hand, initial observations in the 1970s suggested that the

101

cannabis constituent CBD interferes with the detrimental actions of Δ9-THC in terms of psychotic proneness and

102

cognitive dysfunction [17]. Indeed, more recent studies have identified an inverse relationship between CBD

103

content in cannabis strains and the prevalence of psychotic symptoms, such as hallucinations and delusions,

104

suggesting a possible protective effect of CBD [18, 19]. Furthermore, clinical and preclinical studies spanning

105

more than a decade [13, 20-23], demonstrate potential for CBD as an antipsychotic agent against the positive

106

and negative symptoms of schizophrenia (as reviewed in [24]). Despite these findings, evidence of the efficacy

107

of CBD to improve cognitive deficits associated with schizophrenia has not been thoroughly explored. CBD is a

108

particularly interesting target as a novel approach to improving cognition in schizophrenia, in part, due to its

109

strong anti-inflammatory properties [25]. Inflammation, particularly maternal immune activation during

110

pregnancy, is a strong risk factor for schizophrenia pathogenesis and has been linked to the severity of cognitive

111

deficits experienced by individuals [4]. Furthermore, immune system dysfunction has been reported in first

112

episode and antipsychotic-treated schizophrenia patients, implicating this system in the pathogenesis of

113

schizophrenia and as a potential therapeutic target for its treatment [4, 26].

114
115

The aim of the present paper was to provide a detailed systematic literature review of existing preclinical and

116

clinical research examining the effects of CBD on the cognitive domains relevant to schizophrenia, as identified

117

by MATRICS [2]. Research papers included in this review were subdivided into the following categories: 1)

118

studies that examined the ability of CBD to treat cognitive impairment in neuropsychiatric conditions and other

119

neurological disorders, 2) studies that investigated the impact of CBD on cognitive measures during a cannabis

120

or Δ9-THC challenge, or in a healthy state, and 3) studies that examined the effects of CBD in inflammatory-

4

121

based preclinical models of cognitive impairment. Finally, the potential mechanisms of CBD’s action on

122

cognitive function, as well as recommendations for future research are discussed.

123
124

2 Methods

125

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews

126

and Meta-Analyses (PRISMA) guidelines and reporting criteria [27]. The number of studies retained and

127

omitted for this systematic review was recorded for each of the screening stages according to the PRISMA

128

Statement (Figure 1) [27].

129
130

2.1 Search Strategy

131

A literature search was performed using electronic databases (MEDLINE, Web of Science and Scopus) for

132

original, published, English-language research articles, with publication dates spanning from January 1990 to

133

March 2016. Key words included cannabidiol, cognition, cognitive impairment, memory and learning. Different

134

combinations of search terms were used based on the requirements or limitations of each database. For example,

135

the search strategy for Medline was (cannabidiol AND cognition) or (cannabidiol AND cognitive AND

136

impairment). The reference lists of eligible studies were also screened to identify additional studies.

137
138

2.2 Eligibility Criteria

139

Studies eligible for inclusion in this systematic review must have assessed the effect of CBD on cognitive

140

domains relevant to schizophrenia (as defined in MATRICS) and must have been published in English. All

141

studies were initially screened by title and abstract to ensure that only empirical studies related to the topic were

142

included. Original research articles that passed the initial screening were reviewed in full text. Studies were

143

further excluded that: (1) did not test cognitive domains related to MATRICS, used self-reporting measures to

144

generate cognitive scores or focused on other outcomes (e.g. reward/motivation, anxiety), or (2) used

145

standardised cannabis extracts containing both Δ9-THC and CBD, such as oromucosal sprays (Sativex®),

146

without appropriate controls (i.e. Δ9-THC or CBD only groups) to assess the effects of CBD alone.

147
148

2.3 Data Extraction and Analysis

149

Following the screening process, original research articles that fit the criterion were further reviewed and the

150

following information was extracted: author, year of publication, journal of publication, aim of the research,

5

151

sample size, gender, drugs administered and dosage, as well as species and strain for preclinical studies. In

152

addition, details of the CBD intervention were recorded, including the dose, frequency and route of

153

administration, experimental paradigm used, as well as information pertaining to treatment outcomes, such as

154

cognitive tests used (either clinical or behavioural), results of the cognitive testing, results of any biochemical

155

analyses relating to cognition, and the overall conclusion of the research. The detailed information was tabulated

156

and partitioned according to clinical or preclinical research (Tables 1 and 2, respectively).

157
158

3 Literature Search Results

159

The initial search strategy yielded a total of 75 articles from Medline (22 articles), Scopus (25 articles) and Web

160

of Science (28 articles). Duplicate publications were excluded, yielding a total of 39 articles that were screened

161

by title and abstract for eligibility. Nine studies were excluded because they did not use behavioural or clinical

162

tests to assess cognition in the domains identified by MATRICS, they generated cognitive scores through self-

163

reported data or they did not report data from cognitive testing (Supplementary Table 1). Two studies

164

investigating the effects of cannabis, and two studies investigating the effects of Sativex®, were excluded as

165

they either lacked adequate control groups (either Δ9-THC or CBD only groups) to ascertain the effects of CBD

166

alone, or did not report CBD content (Supplementary Table 1). A total of 27 studies passed the screening

167

process and were collated for qualitative synthesis (Tables 1 and 2), including 9 clinical (human) studies

168

(consisting of 1 double-blind, placebo-controlled trial; 1 randomised, double-blind, placebo-controlled trial; 1

169

double-blind, placebo-controlled, cross-over trial; 4 randomised, double-blind, placebo-controlled, cross-over

170

trials and 2 naturalistic, cross-over study designs) and 18 preclinical studies (including 11 mouse, 6 rat and 1

171

non-human primate models). The clinical studies investigated the effects of CBD on: (1) verbal, episodic and

172

recognition memory in cannabis users using naturalistic study designs (n=2); (2) working and social recognition

173

memory, attention, verbal learning and memory and executive function using standardised cannabis extract or

174

∆9-THC challenge paradigms in non-users and cannabis users (n=6); and (3) selective attention in schizophrenia

175

patients (n=1). The preclinical studies included in this review investigated the effects of CBD on cognition in (1)

176

neuropsychiatric modelling of schizophrenia and Alzheimer’s disease (n=6); (2) cannabis and ∆9-THC challenge

177

paradigms and healthy rodents (n=4); (4) neurological conditions, such as brain ischemia, hepatic

178

encephalopathy, as well as pain (n=5); and (4) inflammation-based models of cognitive impairment (n=3).

179

Domains assessed by the preclinical studies aligned with the cognitive domains described in MATRICS and

180

included working memory, object recognition and social recognition memory, associative learning, procedural

6

181

and declarative memory, and spatial learning and memory. In the present review, the literature pertaining to the

182

effect of CBD on cognitive impairment in pathological states is presented separately to the literature examining

183

the effects of CBD on cognition in drug-induced and healthy states.

184
185

3.1 Cannabidiol as a therapeutic intervention for cognitive impairment in neuropsychiatric and

186

neurodegenerative disorders

187

3.1.1 Effects of CBD on cognitive function in schizophrenia

188

There has been limited examination of the clinical efficacy of CBD to treat cognitive dysfunction in

189

neuropsychiatric disorders, with one published study that examined effects in psychiatric patients [28] (Table 1)

190

and two studies that utilised a preclinical model of schizophrenia in rodents [29, 30] (Table 2). A study

191

conducted by Hallak et al [28] investigated the therapeutic efficacy of CBD to improve cognitive deficits in

192

patients with schizophrenia. Testing comprised of two sessions, the first of which subjected participants to a

193

Stroop Colour Word test, followed by a second session (one month later) where participants were administered a

194

single dose of CBD (300 mg or 600 mg) or placebo then performed the Stroop Colour Word test one-hour post-

195

treatment, in order to assess the effects of CBD on selective attention [28]. The number of errors made in the

196

Stroop Colour Word test significantly decreased between testing sessions in both the 300 mg CBD-treated and

197

the placebo groups, with a similar trend observed in the 600 mg CBD-treated group [28]. The improvement

198

across all experimental groups, particularly the placebo-treated group, is indicative of a learning effect rather

199

than a treatment effect; the authors attributed the learning effect to the short (one month) between-test duration

200

[28]. In addition, the lack of a control group (healthy volunteers) in the experimental design makes it difficult to

201

determine if this cohort of individuals with schizophrenia had underlying selective attention deficits in

202

comparison to the general population prior to the commencement of treatment. The only other studies to

203

investigate the efficacy of CBD to treat cognitive deficits associated with schizophrenia were conducted in a

204

preclinical schizophrenia model of N-methyl-D-aspartate (NMDA) receptor hypofunction, using the antagonist

205

MK-801 [29, 30]. A study conducted by Deiana et al [29] administered CBD (5, 12 or 30 mg/kg) 30 minutes

206

prior to MK-801 administration (0.08 mg/kg) and then tested social recognition memory in male Wistar rats.

207

Acute pre-treatment with CBD did not prevent the MK-801-induced deficits in social recognition memory,

208

while CBD administration to control rats had no significant effect on social recognition [29]. In another MK-801

209

(1 mg/kg) study, mice were administered CBD for 22 days then subjected to the Novel Object Recognition

210

(NOR) test [30]. The discrimination index (measured as the ratio of time spent exploring the novel object to the

7

211

total time spent exploring either the novel or familiar objects) was significantly higher in MK-801-treated mice

212

administered 60 mg/kg CBD compared to controls, while 30 mg/kg CBD had no significant effect on the

213

discrimination index [30]. As rodents have a natural tendency to explore novel objects, a reduction in the

214

discrimination index demonstrates impaired object recognition memory [31]. Therefore, the results of these two

215

studies suggest that high doses of CBD can alleviate object recognition memory dysfunction, but not social

216

recognition memory in the MK-801 rodent model of schizophrenia.

217
218

3.1.2 Effects of CBD on cognitive function in Alzheimer’s disease

219

The therapeutic efficacy of CBD to treat cognitive deficits has also been examined in four studies using

220

neurodegeneration rodent models of Alzheimer’s disease (AD) [32-35] (Table 2). A study conducted by Martin-

221

Moreno et al. [32] used intraventricular injection of β-amyloid (Aβ) to model AD, as Aβ plaque formation in the

222

brain is a characteristic feature of AD pathogenesis. Aβ-injected mice displayed increased latency times to find a

223

hidden platform in the Morris Water Maze, indicating impairment to spatial memory [32]. Conversely, Aβ-

224

injected mice administered CBD (20mg/kg) had latency times similar to controls, suggesting that CBD

225

attenuates Aβ-induced deficits in spatial learning and memory [32]. Iron accumulation in the brain is also

226

implicated in the pathogenesis of AD and administration of iron to rodents during the neonatal period mimics

227

the persistent memory deficits observed in Alzheimer’s patients in the clinic [33]. Male rats subjected to iron-

228

overload during postnatal days 12-14 had a significantly lower recognition index during the NOR test compared

229

control rats, indicating impaired recognition memory [33]. Acute CBD administration (10 mg/kg) significantly

230

increased the recognition index of iron-overload rats compared to the vehicle controls, while chronic (2 weeks)

231

CBD administration restored recognition memory in iron-overload rats in both the 5 mg/kg and 10 mg/kg

232

dosage groups [33]. Two studies used a double transgenic mouse model of AD that co-expresses two of the

233

three mutant genes implicated in familial AD pathogenesis, amyloid precursor protein (APP) and presenilin 1

234

(PS1) [36], and exhibits accelerated amyloid pathology and deficits in object and social recognition memory

235

[34, 35]. Chronic CBD administration (20 mg/kg) in APPxPSI mice significantly increased the time spent

236

interacting with the novel object in the NOR test compared to vehicle-treated APPxPSI mice [34],

237

demonstrating improved recognition memory in the CBD-treated mice. In the Social Preference test (which

238

assesses social recognition memory based on the fact that rats prefer to interact with unfamiliar rats) all groups

239

except the vehicle-treated APPxPSI mice demonstrated a preference for the novel rat, suggesting that CBD

240

administration restores social recognition memory in this AD model [34]. On the other hand, CBD treatment did
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241

not affect associative learning in this mouse model of AD, as evidenced during the Fear Conditioning paradigm

242

[34]. A subsequent long-term study (8 months) conducted by the same group investigated the ability of CBD to

243

prevent cognitive deficits associated with AD using the double transgenic APPxPSI mouse model [35]. CBD

244

(20 mg/kg) was administered daily for 8 months, after which time mice underwent a series of behavioural tests

245

(Fear Conditioning Paradigm, Social Preference Test and the Elevated Plus Maze) [35]. The authors confirmed

246

their previous finding of improved social recognition memory with chronic CBD administration, demonstrating

247

that CBD is able to prevent the social recognition memory deficits of AD, but not associative learning deficits

248

[35].

249
250

3.1.3 Conclusions

251

The only clinical trial to investigate the efficacy of CBD to treat cognitive dysfunction in a neuropsychiatric

252

disorder did not find any acute treatment effects of CBD on attention in the Stroop Colour Word test in

253

schizophrenia patients [28]. On the other hand, the two preclinical reports showed that CBD attenuated object

254

recognition memory deficits in an NMDA receptor hypofunction model of schizophrenia, with no effect on

255

social recognition memory [29, 30]. Further research is required to investigate the potential of CBD to improve

256

cognitive deficits in schizophrenia following a long-term CBD treatment period. In addition, to fully ascertain

257

the potential benefits of CBD treatment on cognition in schizophrenia, further studies using tests that align with

258

MATRICS are required. Several preclinical models demonstrate improved recognition, social recognition and

259

spatial memory in AD paradigms following acute and chronic CBD treatment [32-35]. These results may have

260

important implications for the treatment of neurodegenerative disorders; however, extensive randomised,

261

controlled clinical trials are needed to confirm that findings translate to human patients.

262
263

3.2 Effects of CBD on cognition in healthy and drug-induced states

264

Eight studies explored the impact of CBD on cognitive function influenced by cannabis, while no studies have

265

explored the effect of CBD on cognition in other drug-induced states (e.g. opioid, amphetamine, nicotine,

266

alcohol). Two studies examined the influence of CBD on cognitive function in cannabis users during an

267

intoxicated and un-intoxicated state (using their preferred cannabis strains) [37, 38] (Table 1), while 4 studies

268

investigated the effects of CBD on cognitive function following Δ9-THC administration to human participants

269

[39, 40] (Table 1), rats and monkeys [41, 42] (Table 2). Three studies examined the effect of CBD on cognition

270

following administration of standardised cannabis extracts to human participants [43-45] (Table 1). Lastly, three

9

271

studies investigated the effect of CBD alone on cognitive function in healthy participants [46] (Table 1) and rats

272

[47, 48] (Table 2).

273
274

3.2.1 Effects of CBD on cognitive functioning in cannabis users

275

The relative ratio of ∆9-THC and CBD varies greatly in cannabis strains, particularly with the introduction of

276

high potency (high ∆9-THC) strains to the market, such as sinsemilla or ‘skunk’ (20% ∆9-THC: <0.5% CBD)

277

that contain virtually no CBD (compared to previous strains that contained a 2:1 ratio of ∆9-THC:CBD) and are

278

associated with a higher risk of psychosis [49]. Morgan et al [37] investigated the relationship between the CBD

279

content of cannabis strains and cognitive functioning of users. Cannabis users were divided into two groups

280

based on CBD content, ie: low (<0.14%) and high (>0.75%) CBD content groups (n=22 per group), based on

281

sample analysis of the self-provided cannabis that participants smoked during this naturalistic study [37].

282

Participants were tested on verbal and category fluency, prose recall and source memory to assess verbal and

283

episodic memory [37]. This cognitive testing was conducted on two separate occasions: in either drug-free or

284

acutely intoxicated states. During acute intoxication, users of low CBD strains performed significantly worse in

285

the Prose Recall Test compared to users of high CBD cannabis strains, while no changes were observed in

286

Source Memory or Verbal and Category Fluency tests [37]. The cannabis sample analysis revealed no difference

287

in ∆9-THC levels between the two groups; therefore, the results suggest that high cannabis CBD concentrations

288

may be protective against ∆9-THC-induced verbal memory impairments. It is worth noting that the authors

289

identified differences in other parameters between the high and low CBD cannabis groups, including higher

290

alcohol consumption and lower Wechsler Adult Reading Test scores (reflecting reduced verbal memory ability)

291

in the low CBD group; however, these factors were added as covariates in memory data analyses [37]. In

292

addition, the authors suggested that differences in these other parameters were unlikely to explain the difference

293

in verbal memory between the low and high CBD concentration groups during acute intoxication as

294

performance did not differ between the low and high CBD groups during baseline (unintoxicated) testing [37].

295

In another study conducted by the same group, the relationship between cognitive function and the ratio of ∆9-

296

THC to CBD content in plant strains was examined in un-intoxicated chronic cannabis users [38]. Cannabis

297

users were divided into two groups depending on the amount of cannabis they consumed i.e. recreational (n=54)

298

or daily (n=66) users. Cognitive function was tested using Recognition Memory, Prose Recall and Source

299

Memory tests. Additionally, participant hair samples were analysed for cannabinoid content [38]. The two

300

groups were then further subdivided based on the presence or absence of CBD in the hair sample. Individuals

10

301

who consumed cannabis strains containing CBD (as evidenced by the presence of CBD in the hair samples)

302

displayed significantly better recognition memory compared to users who consumed cannabis strains with low

303

CBD, regardless of the degree of cannabis use (daily or recreational) [38]. The presence or absence of CBD in

304

hair samples did not influence Prose Recall or Source Memory test performance; however, when divided based

305

on frequency of cannabis use, daily users of high ∆9-THC cannabis strains performed poorly in these tests

306

compared to users of low ∆9-THC strains [38]. These results demonstrate that daily exposure to high ∆9-THC

307

cannabis is associated with impaired verbal learning and memory, as well as episodic memory [38]. On the other

308

hand, the presence of CBD in cannabis appears to protect against recognition memory impairment in

309

unintoxicated, chronic daily and recreational cannabis users, but has no influence on verbal learning and

310

memory, or episodic memory [38]. These naturalistic studies suggest that CBD may play a protective role in

311

specific aspects of cannabis-induced cognitive impairment; however, considering the numerous constituents

312

found in cannabis, it is difficult to conclude that any protective effects are wholly attributable to CBD.

313
314

3.2.2 Effects of CBD on cognitive function in ∆9-THC administration studies

315

The administration of ∆9-THC is a paradigm that allows investigation of CBD effects on cognition during an

316

intoxicated state while removing the confounding factors associated with natural cannabis, including other

317

cannabis constituents and differing CBD concentrations. For example, Hindocha et al [39] investigated the

318

effects of ∆9-THC or CBD (administered independently or in combination) on emotional facial recognition in

319

cannabis users with a diagnosis of schizotypy. Participants were divided into groups depending on the extent of

320

cannabis use and schizotypy score (n=12 per group). Participants were randomised to receive ∆9-THC (8 mg),

321

CBD (16 mg), ∆9-THC+CBD (8 mg+16 mg) or placebo over 4 drug sessions in a crossover design, with a one

322

week washout period between each session [39]. Participants were presented with faces displaying varying

323

emotional intensity (20-100%), including fearful, angry, happy, sad, surprise and disgust. As expected, the

324

recognition of facial emotion became more accurate with increased intensity across all groups [39].

325

Administration of ∆9-THC significantly reduced performance in the Emotional Processing Task when subjects

326

were presented with faces graded at 40% emotional intensity, while administration of CBD with ∆9-THC

327

improved accuracy of emotion identification compared to the ∆9-THC only group [39]. Interestingly, CBD

328

administration significantly improved accuracy in the emotional processing task beyond placebo levels [39].

329

There was no main effect of frequency of cannabis use or schizotypy diagnosis. Therefore, these results

330

demonstrate that CBD enhanced emotional facial recognition and limited the detrimental effects of ∆9-THC in

11

331

cannabis users, regardless of frequency of use or schizotypy score [39]. Another study conducted by Englund et

332

al [40] directly tested the hypothesis that CBD prevents ∆9-THC-induced cognitive impairment by pre-treating

333

healthy human participants with either CBD or placebo prior to receiving a ∆9-THC challenge (1.5 mg). CBD-

334

treated subjects performed better in delayed recall (during the Hopkins Verbal Learning Task Revised)

335

compared to the placebo pre-treatment group, indicating that CBD treatment prevents verbal learning and

336

memory deficits produced by ∆9-THC [40]. In the Digit Span Forward task, which assesses working memory,

337

the placebo pre-treated group performed significantly worse following the ∆9-THC challenge compared to their

338

corresponding baselines scores [40]. CBD pre-treatment resulted in similar scores to baseline (i.e. prior to the

339

∆9-THC challenge), indicating that CBD limited the detrimental effects of ∆9-THC on working memory [40].

340

CBD pre-treatment was unable to prevent ∆9-THC-induced working memory impairment in the Digit Span

341

Reverse task (also measures working memory), as performance was significantly worse in both groups

342

following the ∆9-THC challenge (CBD and placebo pre-treatment), compared to baseline scores, possibly due to

343

the increased difficulty of this test [40]. Overall, the findings of Englund et al [40] demonstrated that CBD pre-

344

treatment prevents ∆9-THC-induced deficits in verbal learning and memory, and specific (but not all) aspects of

345

working memory in humans. A preclinical study conducted by Hayakaya et al [41] investigated treatment

346

effects of various doses of CBD (3, 10 or 50 mg/kg) on cognition in ∆9-THC pre-treated (1 mg/kg) male mice.

347

Pre-treatment with ∆9-THC impaired mouse performance in the Eight-arm Radial Maze, demonstrating impaired

348

spatial learning and memory [41]. Low doses of CBD (3 mg/kg) restored performance in this test to control

349

levels [41], demonstrating that CBD can improve ∆9-THC-induced deficits in spatial learning and memory. On

350

the other hand, high doses of CBD (50 mg/kg) significantly increased the number of incorrect entries compared

351

to vehicle administration following ∆9-THC pre-treatment. Interestingly, high doses of CBD administered alone

352

did not impair performance in the Eight-arm Radial Maze, suggesting that CBD may potentiate the detrimental

353

effects of ∆9-THC on spatial learning and memory when administered to mice at high doses [41]. Indeed, a

354

previous study demonstrated that pre-treatment with high doses of CBD increased ∆9-THC concentrations in the

355

blood and brain of rats [50], suggesting that a potential mechanism by which high dose CBD enhances ∆9-THC-

356

induced cognitive impairment may be through altered ∆9-THC metabolism. A study conducted by Wright et al

357

[42] examined the effects of CBD on cognition in male Rhesus monkeys following acute ∆9-THC pre-treatment.

358

The CBD/∆9-THC group performed significantly better on the Visuospatial Paired Associates Learning task,

359

which assesses visual learning and memory, compared to the vehicle-treated ∆9-THC group [42]. In addition,

360

CBD limited ∆9-THC-induced deficits in procedural learning, as evidenced during the Rotating Turntables task

12

361

[42]. Conversely, CBD did not improve the ∆9-THC-induced deficits in spatial working memory in the Self-

362

Ordered Spatial Search task. In fact, the CBD treatment group performed significantly worse compared to the

363

control group (no ∆9-THC) [42].

364
365

3.2.3 Effects of CBD on cognitive function using standardised cannabis extract

366

The administration of standardised cannabis extracts (containing a defined ratio of ∆9-THC to CBD) with

367

appropriate control groups (either ∆9-THC or CBD only groups) has also been employed as a paradigm that

368

allows investigation of CBD treatment effects on cognition. For example, Roser et al [43] examined the effects

369

of acute standardised cannabis extract (10 mg ∆9-THC+5.4 mg CBD) or ∆9-THC (10 mg) administration in

370

healthy volunteers. Participants were asked to perform the Choice Reaction task, which assesses selective

371

attention, while the amplitudes of auditory P300 event-related potentials were observed. In this paradigm, a

372

sequence of repetitive tones was randomly interrupted by a tone with a different frequency, to elicit an auditory

373

evoked P300 wave, a cognitive event-related potential (i.e. an electrophysiological response) that is measurable

374

using electroencephalography (EEG). Reduced amplitudes of P300 waves are consistently found in

375

schizophrenia patients, indicating deficient attention and working memory [43]. Reaction times in the Choice

376

Reaction task did not differ between the cannabis extract and ∆9-THC groups; however, both the cannabis

377

extract and ∆9-THC only groups displayed reduced P300 wave amplitudes compared to the placebo group,

378

indicating that CBD was not able to attenuate deficits induced by ∆9-THC in this paradigm [43]. In another

379

study, Schoedel et al [44] investigated the effects of the oromucosal spray Sativex® (GW Pharmaceuticals Ltd.

380

Salisbury, UK) and dronabinol (synthetic THC: Marinol, Solvay Pharmaceuticals, Brussels, Belgium) on the

381

cognitive performance of recreational cannabis users. Participants were administered Sativex® of varying doses

382

(10.8 mg ∆9-THC+10 mg CBD; 21.6 mg ∆9-THC+20 mg CBD; and 43.2 mg ∆9-THC+40 mg CBD), or

383

dronabinol (20 mg and 40 mg ∆9-THC), or placebo (control) and asked to perform several tests of attention and

384

working memory (Choice Reaction Time task, Divided Attention test and the Short-Term Memory test) [44]. No

385

significant effects of treatment were observed in the Choice Reaction Time or Divided Attention tasks; however,

386

high dose dronabinol (40 mg) significantly increased Short-Term Memory test reaction time compared to the

387

placebo [44]. This result was not observed with Sativex® containing both ∆9-THC and CBD suggesting that

388

CBD attenuated the detrimental effect of high dose ∆9-THC on working memory performance in that study [44].

389

Further evidence that cannabis medicinal extracts do not impair cognition was reported by Wade et al [45], who

390

found that administration of medical cannabis (2.5 mg ∆9-THC+2.5 mg CBD) or CBD alone (2.5 mg) to

13

391

multiple sclerosis patients did not affect their performance on the Short Orientation Memory Concentration

392

(SOMC) test compared to placebo, while administration of ∆9-THC (2.5 mg) alone did impair performance.

393
394

3.2.4 Effects of CBD alone on cognitive function in healthy models

395

A study conducted by Bhattacharyya et al [46] investigated the effects of ∆9-THC (10 mg), CBD (600 mg) or

396

placebo on brain activity using neuroimaging techniques (functional magnetic resonance imaging, fMRI) in

397

healthy volunteers while performing cognitive tasks (Verbal Memory task to assess verbal learning and

398

memory, Viewing Fearful Faces task to assess social recognition and Response Inhibition tasks to assess

399

executive function). Interestingly, neither ∆9-THC nor CBD had any effect on cognitive task performance

400

compared to the placebo [46]; a result that coincides with observations in healthy male Sprague-Dawley rats

401

where acute CBD administration had no effect on spatial learning and memory in the Eight-arm Radial Maze

402

[47]. In addition, Ward et al [48] found that acute CBD administration (2, 5 or 20 mg/kg) to female C57Bl mice

403

30 minutes prior to performing an AutoShaping task had no effect on conditioned learning. Contrary to the lack

404

of change in behavioural data reported by Bhattacharyya et al [46], they reported also that ∆9-THC and CBD

405

had opposite effects on regional brain activation while the tasks were being performed [46]. In contrast to ∆9-

406

THC, CBD augmented striatal, anterior cingulate, medial and lateral prefrontal cortical activation during the

407

Verbal Memory task. CBD also increased activation in the parahippocampal gyrus, left insula and caudate

408

nucleus during the Response Inhibition task, while ∆9-THC attenuated activity relative to the placebo [46]. In

409

the Viewing Fearful Faces task, CBD attenuated amygdala activation, which the authors suggest may be due to

410

the anxiolytic properties of CBD [46]. While the 600 mg dose of CBD that was utilised by Bhattacharyya et al

411

[46] had no apparent effect on cognition in healthy volunteers, it is interesting to note the contrasting brain

412

region activation observed between the CBD and ∆9-THC treatment groups and further investigation into the

413

functional implications of the result are warranted.

414
415

3.2.5 Conclusions

416

There is a disparity between studies investigating the effects of CBD on cognitive performance in cannabis users

417

in an intoxicated state and following ∆9-THC challenge. In cannabis-induced cognitive impairment, CBD

418

attenuates deficits in episodic and recognition memory, and verbal learning and memory; however, these

419

beneficial effects vary depending on the duration (acute use vs. chronic use) and frequency (recreational vs.

420

daily) of cannabis use [37, 38]. The results of ∆9-THC challenge studies suggest that CBD can improve visual

14

421

learning and memory, and procedural learning performance [42], while preventing ∆9-THC-induced

422

impairments to verbal learning and memory, and improve some working memory tasks during a ∆9-THC

423

challenge [40], with no effect on spatial learning and memory during ∆9-THC challenge [41]. In contrast, studies

424

investigating the effects of standardised cannabis extracts found no significant effect of CBD on cognitive

425

performance [43, 44], demonstrating that the one-to-one ratio of ∆9-THC to CBD has no detrimental effects on

426

cognition [44]. In addition, pure CBD administered to healthy human participants and rats has no effect on

427

cognition [46-48]. There is some crossover in cognitive improvements between human cannabis and ∆9-THC

428

challenge studies; however, inconsistencies in dosage between these studies pose difficulties in direct

429

comparison of treatment effects. On that note, it is important to consider dosage differences between these

430

studies, i.e. the ratio of CBD to ∆9-THC in the ∆9-THC challenge studies in humans (16 mg CBD: 8 mg ∆9-

431

THC) differed to the ratios in Cannabis sativa strains (1.5% CBD: 12-18% ∆9-THC) [49]. The levels of ∆9-THC

432

used to induce cognitive impairment (preclinical: 0.5, 1.0 mg/kg; clinical: 1.5 mg and a higher dose of 8 mg)

433

and the dose of CBD used in clinical (16 mg and 600 mg) and preclinical studies (0.5, 1, 3, 10 and 50 mg/kg)

434

varied. Future preclinical studies investigating the effects of CBD treatment should consider the translation of

435

CBD doses in animals to human doses, as low doses of CBD in mice had beneficial effects on cognition, whilst

436

high CBD doses enhanced the detrimental effects of ∆9-THC on cognition, possibly by impairing ∆9-THC

437

clearance [41]. The bioavailability, peak concentrations and behavioural effects of cannabinoids vary depending

438

on the route of administration [51], which also differed between the studies reviewed in this section (∆9-THC

439

and CBD were administered orally [40, 43-46] or inhaled [39] in the clinical studies, while the preclinical

440

studies used intramuscular [42] and intraperitoneal injections [47, 48]). Therefore, due to the differences in dose

441

and route of administration, it is difficult to draw comparisons between the studies. Finally, although CBD is the

442

main non-intoxicating component of cannabis, the plant contains over 70 different cannabinoids and, therefore,

443

only associations can be drawn from studies investigating the effects of cannabis on cognition. Overall, further

444

research is required to elucidate the therapeutic benefits of CBD on cognitive impairment in cannabis users and

445

following ∆9-THC administration in healthy participants.

446
447

3.3 Cannabidiol as a therapeutic intervention for cognitive impairment in neurological disorders

448

3.3.1 Effects of CBD on cognitive functioning in preclinical brain ischemia models

449

Two studies have investigated the effects of CBD on cognitive impairment in preclinical models of brain

450

ischemia [52, 53] (Table 2). Ischemic brain injury produces irreversible changes in the brain, including neuronal
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451

damage and apoptosis that result in impaired memory, attention and executive functioning [52, 53]. A study

452

conducted by Pazos et al. [52] investigated the effects of CBD administration on cognition in Wistar rats

453

exposed to hypoxic-ischemic (HI) brain injury after birth, modelled using left common carotid artery

454

electrocoagulation techniques. Rats were administered a single subcutaneous injection of either CBD (1 mg/kg)

455

10 minutes post-HI induction and were subjected to the NOR test. Vehicle-treated HI rats had less preference

456

for the novel object compared to non-HI (sham) rats [52], indicating impairment to recognition memory in the

457

model. Interestingly, CBD administration attenuated this deficit, returning novel object preference to control

458

(sham) levels [52]. Spatial learning and memory deficits were observed in a similar model of brain ischemia in

459

adult rodents [53]. In a study by Schiavon et al [53], groups of mice were administered either CBD (3, 10 or 30

460

mg/kg) or vehicle, 30 minutes prior to a bilateral common carotid artery occlusion to induce brain ischemia (or

461

sham surgery for controls). Mice were then treated again with CBD or vehicle 3, 24 and 48 hours post-surgery,

462

and then underwent a Morris Water maze test one-week post-surgery to examine treatment effects on spatial and

463

memory performance [53]. Vehicle-treated ischemic mice took longer to find the submerged platform than

464

control mice, indicating impaired spatial learning and memory in the ischemia model [53]. On the other hand,

465

mice treated with CBD (pre- and post-surgery 3, 10, or 30 mg/kg) had a lower latency to find the platform than

466

vehicle-treated ischemic mice, indicating that CBD prevented the spatial learning and memory deficits induced

467

by ischemia [53]. Taking both ischemia model studies into consideration, CBD appears to have a

468

neuroprotective role and is able to both attenuate and prevent the learning and memory deficits induced by brain

469

hypoxia.

470
471

3.3.2 Effects of CBD on cognitive functioning in preclinical hepatic encephalopathy models

472

Hepatic encephalopathy (HE) is a disorder that occurs due to build-up of toxic substances in the bloodstream

473

during acute and chronic liver failure. HE manifests symptoms such as personality disturbances, impairments to

474

muscular co-ordination, attention and other cognitive deficits [54-56]. In rodents, exposure to the hepatotoxin

475

thioacetamide (TAA) is used to model acute HE [54], while chronic HE is induced by bile duct ligation (BDL)

476

[55, 56]. Three preclinical studies involving HE modelling of cognitive impairment were identified during the

477

literature search. In one study, acute CBD administration (5 mg/kg) improved the performance of TAA mice

478

compared to vehicle-treated TAA mice in the eight-arm maze test, a measure of spatial learning and memory

479

[54]. Another two studies investigated the effects of chronic CBD administration at the same dose (5mg/kg)

480

using a chronic model of HE induced by BDL [55, 56]. Female Sabra mice subjected to BDL displayed a
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481

significantly higher percentage of entries in the Eight-Arm Radial Maze compared to sham-treated mice 3 weeks

482

post-surgery, demonstrating spatial learning and memory impairment in this model [55, 56]. Following 4 weeks

483

of CBD treatment, CBD-treated BDL mice had a lower percentage of errors compared to vehicle-treated BDL

484

mice, indicating that chronic CBD administration improves spatial learning and memory in this model [55, 56].

485

Likewise, BDL mice performed significantly worse in the T-Maze test compared to the Sham group, while CBD

486

administration increased the number of entries, suggesting improved working memory by CBD in BDL mice

487

[55]. Overall, these results suggest that chronic CBD treatment can attenuate working memory deficits, while

488

improving spatial learning and memory with both acute and chronic treatment in a HE model.

489
490

3.3.3 Conclusions

491

The effect of CBD on cognitive function in neurological disorders has been investigated in preclinical models of

492

brain ischemia and HE. Acute CBD administration improved recognition memory following impairment due to

493

brain ischemia and prevented spatial learning and memory deficits [52, 53]. Acute and chronic CBD

494

administration improved the spatial learning and memory, and working memory deficits induced by HE [54-56].

495

The evidence investigating the efficacy of CBD to treat cognitive impairment in neurological disorders is

496

limited and further investigation of the apparent neuroprotective effect of CBD is warranted.

497
498

3.4 Cannabidiol as a therapeutic intervention in inflammation-based models of cognitive impairment

499

The link between the immune system and cognition has been well established [4, 57] as inflammatory states,

500

including increased pro-inflammatory signalling, have been linked to cognitive dysfunction [4]. In healthy

501

people, increased levels of pro-inflammatory cytokines (small molecules involved in immune system signalling)

502

have been associated with poor performance in tasks that assess recognition and working memory, attention and

503

executive function; cognitive domains that are affected in schizophrenia [58, 59]. In the current review, three

504

preclinical studies investigated the effect of CBD on cognition using inflammation-based models [60-62] (Table

505

2). One study used cecal ligation and puncture (CLP) as a model of systemic inflammatory disease (sepsis) that

506

leads to neurological abnormalities including disorientation, lethargy, confusion and coma [60]. The authors

507

assessed the effect of acute and sub-chronic CBD administration on cognitive function and oxidative parameters

508

in male Wistar rats following CLP induction [60]. In the first experiment, rats received an acute injection of

509

CBD (2.5, 5 or 10 mg/kg) immediately after CLP and were sacrificed after 6 hours [60]. In the second

510

experiment, rats received sub-chronic CBD administration (2.5, 5 or 10 mg/kg daily for 9 days) following CLP
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511

induction and were subjected to the Inhibitory Avoidance task, which measures associative learning [60]. Both

512

the vehicle-treated sham rats and CBD-treated CLP rats improved performance between training and test

513

sessions demonstrating a positive learning and memory effect; however, no significant difference was observed

514

in vehicle-treated CLP rats, indicating memory impairment due to sepsis [60]. The improvement in associative

515

learning by CBD treatment was evident not only at the same effective dose used in the HE models (5 mg/kg)

516

[54-56], but also at lower (2.5 mg/kg) and higher (10 mg/kg) doses of CBD. Overall, these results suggest that

517

sub-chronic CBD administration can attenuate the associative learning deficits produced in the CLP-induced

518

sepsis model over a range of doses.

519
520

In a study conducted by Barichello et al [61], male Wistar rats were administered a S.pneumoniae injection,

521

which is used to model pneumococcal meningitis. Approximately one third of survivors of pneumococcal

522

meningitis infection present with long-term cognitive impairment, including poor performance in memory tasks

523

and generalised ‘cognitive slowing’ [63], possibly due to the infiltration of pro-inflammatory molecules in the

524

brain [61]. Following pneumococcal meningitis induction, rats displayed impaired associative learning in the

525

Inhibitory Avoidance task, a result that was not apparent in the sham treatment group. Importantly, sub-chronic

526

(9 days) CBD administration (10 mg/kg, but not 2.5 or 5 mg/kg) restored associative learning in the

527

pneumococcal meningitis model of cognitive impairment [61]. Therefore, similar to the CLP-induced sepsis

528

model, sub-chronic administration of CBD can also attenuate the deficits in associative learning produced by

529

pneumococcal meningitis. Campos et al [62] induced cerebral malaria in mice using Plasmodium berghei-

530

ANKA (PbA) infection. Cerebral malaria manifests as seizures, headache, severe cognitive impairment and

531

often results in death in humans [62]. Three days post infection mice were administered CBD (30 mg/kg) or

532

vehicle, followed by treatment with the anti-malarial drug, Artesunate, at the peak of the infection (5 days post

533

infection) [62]. Behavioural testing 5 days post-infection showed that vehicle-treated PbA/Artesunate mice

534

performed significantly worse on the NOR test and Morris Water maze, demonstrating persistent recognition

535

and spatial memory impairments following malaria treatment [62]. On the contrary, PbA/Artesunate mice

536

treated with CBD performed the memory tasks at control levels, indicating that CBD prevents PbA-induced

537

cognitive deficits [62]. Based on these results, the authors suggested that CBD may be a potential adjunctive

538

therapy for the treatment and/or prevention of the neurological deficits that result from cerebral malaria.

539
540

3.4.1 Conclusions
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541

Overall, inflammatory-based models of cognitive impairment consistently show that short-term and long-term

542

CBD administration can attenuate deficits in spatial learning and memory, recognition memory and associative

543

learning [60-62], which are cognitive domains affected in schizophrenia, as identified by MATRICS [2]. Given

544

that CBD can improve cognition in preclinical models of inflammation-induced cognitive dysfunction it is

545

reasonable to speculate that CBD may improve cognition in preclinical models of schizophrenia, particularly as

546

growing evidence suggests an underlying immune dysfunction in the pathogenesis of this disorder [4].

547
548

4 Potential mechanisms underlying CBD’s effects on cognition

549

The present literature review provides the first systematic analysis of the available clinical and preclinical

550

evidence on the effects of CBD on cognitive function. The limited evidence investigating the impact of CBD on

551

cognitive deficits in neuropsychiatric disorders showed that CBD had no effect on selective attention in

552

schizophrenia outpatients [28], while CBD administration attenuated object recognition memory impairment

553

[30], but was unable to prevent social recognition memory deficits induced by MK-801 administration in

554

rodents [29]. In preclinical models of AD, CBD treatment improved social and object recognition memory, with

555

no effect on associative learning [32-35]. No human clinical evidence of CBD treatment effects on cognition in

556

AD could be located during this literature search. The limited studies conducted in neurological disorders

557

suggest that CBD has therapeutic benefits for spatial learning and memory, and recognition memory deficits

558

induced by hypoxic brain injury [52, 53]. In preclinical models of hepatic encephalopathy, acute and chronic

559

CBD administration improved spatial learning and memory, and working memory impairments [54-56]. CBD

560

administration improved learning and memory function in preclinical models of inflammatory disorders such as

561

sepsis [60], pneumococcal meningitis infection [61] and cerebral malaria [62]. In cannabis users, exposure to

562

CBD attenuated episodic and recognition memory, and verbal learning and memory deficits; however, these

563

beneficial effects varied depending on the duration and frequency of cannabis use [37, 38]. In ∆9-THC challenge

564

studies, CBD intervention showed improvement in several cognitive domains (visual learning and memory,

565

procedural learning, verbal learning and memory, and working memory tasks) [40, 42]. CBD dosage is

566

particularly important to consider for ∆9-THC paradigms as low dose CBD had no effect on spatial learning and

567

memory, while high CBD doses potentiated the detrimental effects of ∆9-THC [41]. Some studies using

568

standardised cannabis extracts showed that CBD limited the detrimental effects of ∆9-THC on cognitive

569

function [44, 45], while another study reported contrary findings of no effect [43]. Overall, CBD administration

570

appears to improve cognitive deficits in several domains, with no effect on cognitive function outside
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571

pathological and drug-induced states (i.e. healthy humans and animals) [46-48]. The neurobiology of cognition

572

itself is not yet fully understood, but a vast body of evidence demonstrates the involvement of multiple neural

573

networks with complex interactions between various signalling systems [3, 64]. Therefore, it is highly unlikely

574

that CBD’s mechanism of action can be wholly attributed to one specific signalling pathway or system. Indeed,

575

the preclinical studies included in this review demonstrate changes in multiple biochemical parameters; such as

576

inflammatory and oxidative stress markers, as well as serotonin and adenosine neurotransmitter signalling,

577

following CBD treatment of cognitive impairment. The role of these systems in the potential mechanisms

578

underlying the effect of CBD on cognitive function is discussed below.

579
580

4.1 Effects of CBD on neuroinflammatory markers

581

Preclinical models of cognitive impairment (see Sections 3.1 to 3.3 of this review) showed that CBD treated

582

cognitive dysfunction in areas of working and recognition memory, associative and spatial learning and

583

memory, and social recognition memory [30, 32-35, 53-56, 60-62]. A number of these preclinical studies also

584

assessed neuroinflammatory markers, including cytokine levels and expression, microglial activation and

585

astrogliosis [32, 55, 56, 61]. Signalling of the pro-inflammatory cytokine, tumour necrosis factor-alpha (TNF-α)

586

was significantly increased in the hippocampus and frontal cortex of preclinical models that exhibited HE or

587

AD-induced spatial learning and memory, working memory and associative learning impairments [32, 55, 56,

588

61]. Improved spatial learning and memory, as well as working memory following CBD administration has been

589

associated with down-regulated hippocampal TNF-α and tumour necrosis factor-alpha receptor 1 (TNFRSF1)

590

mRNA expression, with no change in cortical expression [32, 55, 56]. On the other hand, another study reported

591

down-regulated TNF-α levels in the frontal cortex but not in the hippocampus following CBD administration

592

and improved associative learning [61]. Conversely, cortical TNF-α mRNA expression did not change in AD

593

rats exhibiting CBD-induced social recognition memory improvements [35]. Therefore, the literature is

594

confounding but does suggest a possible involvement of TNF-α and TNFRSF1 signalling in the mechanisms

595

underlying the ability of CBD to improve specific aspects of cognition. In addition, one study reported that

596

expression of the pro-inflammatory cytokine interleukin-6 (IL-6) in the cerebral cortex was not altered by CBD

597

treatment, suggesting that the spatial learning and memory improvements observed in the AD model may not be

598

related to changes in IL-6 signalling [32]. Overall, caution may prudent when interpreting the TNF-α and IL-6

599

results as these studies did not examine both protein and mRNA expression levels, which is important because

600

changes in mRNA expression do not always correlate with changes in functional protein levels [65]. Therefore,
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601

to elucidate the role of pro-inflammatory cytokines in the improvement of cognition following CBD treatment,

602

further studies investigating protein and mRNA expression, as well as receptor and downstream signalling

603

pathways in brain regions relevant to the domains assessed by cognitive testing is required.

604
605

Studies presented in this review have also investigated the reactivity of immune cells in the brain (such as

606

microglia and astrocytes) in an effort to explain the mechanism of CBD’s apparent therapeutic effects on

607

cognitive impairment. In neuroinflammatory states, activation of these immune cells leads to the release of pro-

608

inflammatory cytokines that can ultimately result in neuronal cell death [66]. Several preclinical models of

609

cognitive impairment discussed in this review exhibit altered astrocyte and microglial activation [30, 53, 54].

610

For example, in the model of brain ischemia an increased number of active astrocytes was observed [54], while

611

CBD treatment reduced the number of activated astrocytes. This finding was observed using glial fibrillary

612

acidic protein (GFAP) immunohistochemistry methods to measure reactive astrogliosis (an abnormal increase in

613

astrocytes in response to neuronal death), whereby the number of GFAP-positive cells provided an index of

614

neuroinflammation [54]. Therefore, these results demonstrate that CBD treatment reduces neuroinflammation in

615

this preclinical model of brain ischemia. Astrogliosis was also observed in the MK-801 model of schizophrenia;

616

however, there was no effect of CBD treatment on GFAP-positive cell number indicating that CBD did not

617

attenuate astrogliosis [30]. On the other hand, increased expression of the microglial activation marker, Iba 1,

618

was observed in MK-801-treated rats, while CBD treatment attenuated microglial activation in the medial

619

prefrontal cortex and CA1 region of the hippocampus, but not in the dentate gyrus [30]. Overall, the results from

620

these studies imply that decreasing the pro-inflammatory immune response may serve as a potential mechanism

621

by which CBD treatment restores cognitive function in pathological states. Considering the robust anti-

622

inflammatory properties of CBD [67], and the evidence that inflammation is implicated in cognitive deficits (as

623

reviewed in [4]), more research along this line of investigation seems imperative.

624
625

4.2 Effects of CBD on oxidative stress parameters

626

Two studies included in the present review investigated the link between oxidative stress and cognitive

627

performance [35, 60]. Oxidative damage to lipids was present in the striatum of cognitively impaired CLP

628

(sepsis) rats, which was determined by measuring the levels of thiobarbituric acid reactive substances (TBARS,

629

a by-product of lipid peroxidation and indicator of oxidative stress) [60]. Striatal TBARS levels were attenuated

630

by acute CBD administration [60]. Furthermore, sub-chronic CBD administration attenuated hippocampal CLP-
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631

induced lipid oxidative damage and decreased protein carbonyl levels (an indicator of protein damage)

632

compared to controls [60]. In contrast, another study found no change in the oxidative stress marker, F2-

633

isoprostanes, in the hippocampus following long-term CBD administration in a double transgenic mouse model

634

of AD [35]. Overall, these studies suggest a specific effect of CBD on oxidative stress parameters in brain

635

regions implicated in learning and memory; however, the results seem dependent on the pathological state and

636

the oxidative stress marker measured.

637
638

4.3 Effects of CBD on neurogenesis and neurotransmission

639

In addition to increased pro-inflammatory signalling (see Section 4.1.1), a decrease in protein levels and gene

640

expression of brain-derived neurotrophic factor (BDNF), a neurotrophic factor critical for learning and memory,

641

was observed in preclinical models of HE and meningitis [55, 56, 61]. BDNF plays an important role in the

642

maintenance and survival of neurons, as well as the growth and differentiation of new neurons and synapses.

643

CBD administration significantly increased hippocampal BDNF mRNA expression in the HE model [55, 56].

644

Hippocampal BDNF levels were not affected by induced meningitis; however, levels in the frontal cortex were

645

decreased and this deficit was restored by CBD treatment [38]. Immunohistochemistry and immunofluorescence

646

techniques have confirmed an increase in hippocampal neurogenesis following CBD administration in a rat

647

model of AD [68]. Therefore, these studies suggest that CBD may promote neurogenesis by increasing BDNF

648

levels, changes in which may correlate with improved functional outcomes in cognition; however, further

649

studies are required to confirm.

650
651

Several studies presented in this review have also investigated the effects of CBD on serotonin and adenosine

652

signalling, due to the role of these neurotransmitters in cognition and inflammation [54-56]. The adenosine A2

653

receptor (A2AA-R) mediates the effects of BDNF on long-term potentiation and synaptic transmission [55]. Co-

654

administration of CBD with the A2AA-R antagonist, ZM241385, to cognitively impaired BDL mice blocked

655

CBD-induced improvements in performance in the Eight-arm Radial Maze [55]. This blockade in performance

656

was concurrent with reduced hippocampal TNF-α 1 receptor expression and elevated levels of BDNF expression

657

[55]. Furthermore, ZM241385 administration had no effect on the cognitive function of Sham or BDL mice that

658

did not receive CBD treatment [55]. The authors suggested that CBD may be an indirect agonist of A2AA-Rs

659

[55]; indeed, another study found that CBD inhibits adenosine uptake from synaptic terminals prolonging the

660

effects of adenosine on its receptors [69]. In addition to adenosine, two preclinical studies included in this

22

661

review investigated the influence of CBD on serotonin 5-hydroxytryptamine (5-HT) signalling in the brain in

662

relation to cognition [54, 56]. In a model of HE that exhibited deficits in spatial learning and memory, whole

663

brain 5-HT levels were significantly up regulated compared to controls, while acute CBD administration

664

attenuated this increase in brain 5-HT levels [54]. In addition, 5-HT1A receptor blockade prevented CBD

665

improvements in spatial memory in BDL mice while (paradoxically) decreasing hippocampal TNF-α 1 receptor

666

expression, with no effect on BDNF expression [56]. Overall, these studies suggest an involvement of serotonin

667

5-HT1A and adenosine A2A receptors in the mechanisms underlying CBD-induced improvements in cognition;

668

however, further research is required.

669
670

5 Conclusions and Future Directions

671

In conclusion, the studies presented in the current review demonstrate that CBD has the potential to limit Δ9-

672

THC-induced cognitive impairment and improve cognitive function in various pathological conditions. Human

673

studies suggest that CBD may have a protective role in Δ9-THC-induced cognitive impairments; however, there

674

is limited human evidence for CBD treatment effects in pathological states (e.g. schizophrenia). Preclinical

675

evidence suggests that overall CBD improves functioning in cognitive domains of learning and memory, in both

676

Δ9-THC-induced and pathological states of cognitive impairment. Importantly, studies generally show no impact

677

of CBD on cognitive function in a ‘healthy’ model, that is, outside drug-induced or pathological states. Current

678

studies investigating drug-induced or pathological states of cognitive impairment, lack consensus on basic

679

experimental parameters, including effective dose ranges, route of administration, frequency and duration of

680

dosing needed to elicit optimal cognitive outcomes. In terms of schizophrenia, CBD has shown potential to treat

681

the positive and negative symptoms of the disorder in both patients and rodent preclinical models [reviewed in

682

24]. There is limited evidence investigating the therapeutic efficacy of CBD to treat the cognitive deficits of

683

schizophrenia; however, CBD treatment improves cognitive function in other neurological disorders,

684

neuropsychiatric and neuroinflammatory models of cognitive impairment. Therefore, well-designed,

685

randomised, controlled trials conducted in schizophrenia patients will be essential to fully elucidate the potential

686

of CBD to improve cognitive deficits in this disorder. The assessment of biochemical markers, such as

687

circulating inflammatory (cytokines, chemokines) and oxidative stress markers, would be useful to determine

688

the immune profiles of treated patients and whether this correlates with any CBD-induced improvements in

689

cognition. Furthermore, future preclinical studies investigating the underlying mechanisms of action of CBD

690

would benefit from using a wide range of behavioural tests that align with MATRICS, to cover the range of

23

691

cognitive domains impaired in schizophrenia patients. In addition, the use of preclinical models of schizophrenia

692

would assist in understanding the neurochemical signalling pathways that CBD acts upon to exert its effects on

693

cognition function. The overall importance of this area of research is emphasized by the large percentage of

694

patients who experience cognitive deficits, the impact on their lives and the lack of therapeutic agents currently

695

available to treat the cognitive symptoms of schizophrenia. This justifies the need for further research to

696

evaluate the potential of CBD as a new intervention for cognitive impairment in schizophrenia.

697
698
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Figure 1: Prisma Flow Diagram for systematic research and identification of studies meeting inclusion criteria

949

(see methods) for systematic review.
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Table 1: Clinical studies investigating the effects of cannabidiol on cognition

Author/Year
Wade et al.
2003
Roser et al.
2008

Study Type
Double-blind,
randomised, placebocontrolled, cross-over
Double-blind,
placebo-controlled,
cross-over

Sample Population/Size
Multiple sclerosis (n=18), spinal
cord injury (n=4), brachial plexus
damage (n=1) and amputation (n=1)
Healthy volunteers (n=20; 10M,
10F)

Intervention
THC (2.5 mg), CBD (2.5 mg) or
cannabis extract (2.5 mg
THC+2.5 mg CBD)
THC (10 mg), cannabis extract
(10 mg THC+5.4 mg CBD) or
placebo

Bhattacharyya
et al. 2010

Double-blind,
randomised, placebocontrolled, cross-over

Healthy male volunteers (n=15)

THC (10 mg), CBD (600 mg) or
placebo

Hallak et al.
2010

Double-blind,
placebo-controlled

Schizophrenia outpatients (n=28;
18M, 10F)

CBD (300 mg or 600 mg) vs
placebo

Morgan et al.
2010

Naturalistic study

Cannabis users (n=134) divided into
low (0.08%) vs. high (4.61%) CBD
groups

Tested in DFS and AIS (with
participant’s chosen cannabis)

Schoedel et al.
2011

Randomised doubleblind, placebocontrolled, cross-over

Recreational cannabis users (n=23;
19M, 4F)

Nabiximols (10.8mg THC+10 mg
CBD, 21.6 mg THC+20 mg CBD
and 43.2 mg THC+40 mg CBD)
or dronabinol (20 or 40 mg THC)

Naturalistic study

Cannabis users (n=120; 89M, 31F)
divided into recreational (n=54) or
daily users (n=66)

Morgan et al.
2012

Englund et al.
2013

Hindocha et al.
2015

Randomised, doubleblind, placebocontrolled

Randomised, doubleblind, placebocontrolled, cross-over

Healthy volunteers; CBD (n=22) vs.
placebo (n=26)

Cannabis users (n=48; 34M, 14F),
divided into light (n=24) and heavy
(n=24) users

Tested in DFS, hair samples
analysed for cannabinoid content
(CBD vs. no CBD)

Pre-treatment with 600 mg CBD
or placebo prior to THC
challenge (1.5 mg)

∆9-THC (8 mg), CBD (16 mg),
∆9-THC+CBD (8 mg +16 mg) or
placebo

Clinical Test

Cognitive Domain

Short Orientation Memory
Concentration Test

attention

Effect of CBD
≈

Choice Reaction Task

processing speed,
attention

Verbal memory task

verbal memory

Viewing fearful faces task

social recognition

Response inhibition (Go No-Go)

executive function

Stroop Word Colour

attention

≈

Prose Recall
Source Memory
Verbal category & fluency
Choice Reaction Time
Divided Attention test

verbal memory
episodic memory
executive control
processing speed
attention

DFS
≈
≈
≈
≈
≈

Short-Term Memory test
Prose Recall

working memory
verbal memory

≈
≈

Recognition memory

recognition memory

↑

Source Memory

episodic memory

≈

HVLTR

verbal learning and
memory

↑

Symbol Coding

working memory

≈

NAB mazes

executive function

≈

≈

≈

AIS
↑
≈
≈

Digit Span Forward

working memory

≈

Digit Reverse

working memory

≈

Emotional processing task

social recognition

↑∆9-THC+CBD vs. ∆9-THC
↑ CBD vs. placebo

Abbreviations: n – number; M – male; F – female; CBD – cannabidiol; THC - tetrahydrocannabinol; HVLTR – Hopkins Verbal Learning Task Revised; DFS – drug-free state; AIS – acute intoxication state; IR –
immediate recall; DR – delayed recall; NAB – Neuropsychological Assessment Battery; ‘↑’ - significant improvement in cognition with CBD administration; ‘≈’ – no change in cognition with CBD administration;
‘↓’– significant impairment in cognition with CBD administration
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Table 2: Preclinical studies investigating the effects of cannabidiol on cognitive function

CBD dose (mg/kg)
Author/Year

Sex

Strain/Species

Experimental Paradigm

Behavioural test

Cognitive domain

Lichtman et al.
1995

M

SpragueDawley rats

Healthy rats administered cannabinoids
(WIN-55, 212-2, CP-55, 940, anandamide,
CBD)

Radial arm maze

Spatial

Hakawaya et al
2008

M

ddY mice

∆9-THC challenge (1 mg/kg)

Eight-arm maze

Spatial

Magen et al. 2009

F

Sabra mice

Hepatic encephalopathy via BDL

Eight-arm maze

Spatial

↑

T-maze

Working

↑
↑

Magen et al. 2010

F

Sabra mice

Hepatic encephalopathy via BDL

Eight-arm maze

Spatial

Cassol-Jr et al. 2010

M

Wistar rats

Sepsis via CLP

Inhibitory avoidance

Associative

Avraham et al. 2011

F

Sabra mice

Hepatic encephalopathy via TAA (200
mg/kg)

Eight-arm maze

Spatial

Martin-Moreno et
al. 2011

F/M

C57Bl/6 mice

Aβ intraventricular injection AD model

MWM

Spatial

Barichello et al.
2012

M

Wistar rats

Meningitis model

Inhibitory avoidance

Associative

Fagherazzi et al.
2012

M

Wistar rats

AD via iron overload (30
mg/kg iron)

NOR

Recognition

Acute

0.5

1.0

2.0

2.5

3.0

5.0

10

12

20

30

50

60

≈

≈

↑

≈

↑

↓

↑

↑

↑

≈

Chronic

≈

↑

≈

↑

↑

↑

↑

Pazos et al. 2012

F/M

Wistar rats

Hypoxic ischaemic injury via
electrocoagulation

NOR

Recognition

Wright et al. 2013

M

Rhesus monkey

∆9-THC challenge (0.5 mg/kg)

vsPAL

Declarative

↑

SOSS

Spatial

≈
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Cheng et al. 2014

M

AβPPxPSI mice

AβPPxPSI double transgenic AD model

≈

RTT

Procedural

NOR

Recognition

↑

Social Preference

Social recognition

↑

Fear Conditioning

Associative

≈
↑

Cheng et al. 2014

M

AβPPxPSI

AβPPxPSI double transgenic AD model

Social Preference

Social recognition

Schiavon et al. 2014

M

Swiss mice

Hypoxic ischaemic injury via BCCAO

MWM

Spatial learning

Ward et al 2014

F

C57Bl/6 mice

Healthy rats

Autoshaping task

Associative

Campos et al. 2015

F

C57Bl/6 mice

CM via PbA + antimalarial Artesunate
(32mg/kg)

NOR

Recognition

↑

MWM

Spatial

↑

Deiana et al. 2015

M

Wistar rats

MK-801 (0.08 mg/kg) model of
schizophrenia

Social Preference

Social recognition

Gomes et al. 2015

M

C57Bl/6 mice

MK-801 (1 mg/kg) model of
schizophrenia

NOR

Recognition

↑
≈

↑

↑

≈

≈

≈

≈

≈

≈

↑

Abbreviations: F – female; BDL – bile duct ligation; CBD – cannabidiol; M – male; CLP – cecal ligation and puncture; TAA – thioacetamide; AD – Alzheimer’s disease; MWM – Morris Water Maze; NOR – novel
object recognition test; ∆9-THC - ∆9-tetrahydrocannabinol; vsPAL – visuospatial paired associate learning task; SOSS – self-ordered spatial search task; RTT – rotating turntables task; BCCAO – bilateral common
carotid artery occlusion; PAC – paclitaxel; CM – cerebral malaria; PbA – Plasmodium berghei-ANKA; ‘↑’ - significant improvement in cognition with CBD administration; ‘≈’ – no change in cognition with CBD
administration; ‘↓‘ – significant impairment in cognition with CBD administration
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Supplementary Table 1: Characteristics of studies excluded from the systematic review
Author/Year
da Silva et al.

Journal of publication
Molecular Neurobiology

2014 [71]

Database

Type of study

Study design

Reason for exclusion

Web of

Experimental rat model

Chronic CBD administration for 14 days to rats subjected to neonatal iron

No behavioural tests were performed

Science

(male Wistar rats)

overload as a model of neurodegenerative disorders. Western blot and real-time

to assess cognition.

PCR analysis of brain proteins associated with mitochondrial fusion and fission
mechanisms.
Liput et al.

Pharmacology Biochemistry

2013 [72]

and Behaviour

Long et al.

PLoS ONE

Scopus

Scopus

2012 [73]

Experimental rat model

Acute CBD intervention via transdermal delivery vs. i.p. in rats submitted to

No behavioural tests were performed

(male Sprague-Dawley

alcohol-induced neurodegeneration. Assessed neuron degeneration via Fluoro-

to assess cognition.

rats)

Jade B staining methods.

Experimental mouse model

Acute and long-term CBD intervention (dose) in a Nrg1 HET mouse model of

No behavioural tests were performed

(female C57Bl/6 mice)

schizophrenia

to assess cognition (data on NORT

Double-blind, randomized,

Intervention with cannabis extract Sativex (1:1 ratio of ∆9-THC: CBD) in

No groups to control for ∆9-THC or

testing was not reported).
Aragona et

Clinical Neuropharmacology

al. 2011 [74]

Scopus,
Medline

placebo-controlled, parallel

cannabis-naïve MS patients (n=17). Assessed on PASAT (measures attention

CBD effects alone (only Sativex vs.

group cross-over trial

and information processing) and self-reported measures of symptoms, quality of

placebo).

Scopus,

Double-blind, placebo-

Drug-naïve Social Anxiety Disorder patients received either CBD (600mg) or

No behavioural tests were performed

Medline

controlled

placebo 1.5h prior to the SPST, vs. healthy controls (no medication). Assessed

to assess cognition.

life, anxiety and fatigue.
Bergamaschi

Neuropsychopharmacology

et al. 2011
[75]
Lafuente et

physiological measures and subjective scores on the VMAS and SSPS-N.
Paediatric Research

Scopus

al.2011 [76]

Experimental newborn

CBD intervention (0.1 mg/kg) 15 and 240 min post-HI induction in newborn

No behavioural tests were performed

piglet model

piglets. Assessed neurophysiological and neurobehavioral scores and performed

to assess cognition.

histological and biochemical analyses.
Winton-

Neuropsychopharmacology

Brown et al.

Web of

Double-blind, pseudo-

Acute intervention with ∆9-THC (10 mg), CBD (600 mg) or placebo to healthy

No behavioural tests were performed

Science

randomized, cross-over

volunteers (n=14). Assessed cannabinoid blood levels, physiological

to assess cognition.

design

parameters, psychopathology, sensory stimulation task.

Scopus,

Prospective, double-blind,

Intervention with ∆9-THC alone or standardised cannabis extract (∆9-THC +

No behavioural tests were performed

Medline

placebo-controlled, cross-

CBD) in healthy volunteers (n=22) and assessed effects on MMN amplitudes.

to assess cognition.

2011 [77]
Juckel et al.

Schizophrenia Research

2007 [78]

over
Niyuhire et

Journal of Pharmacology and

Web of

Experimental mouse model

Intervention with marijuana (50, 100 or 200 mg), ∆9-THC (1, 3 or 10 mg/kg) or

Did not use standardised cannabis

al. 2007 [79]

Experimental Therapeutics

Science

(male C57BL/6 mice)

placebo and tested in the Morris water maze (spatial learning and memory).

extract, level of CBD unknown.
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Ilan et al.

Behavioural Pharmacology

2005 [80]

Scopus,

Double-blind, placebo-

Intervention with marijuana cigarettes containing ∆9-THC (high or low) with

Use of CBC in paradigm without a

Web of

controlled, mixed between

CBC (high or low) and CBD (high or low) in healthy cannabis users (n=23).

CBD only group – cannot determine if

Science

and within-subjects design

Assessed physiological measures (blood pressure, heart rate), cognitive test

effects are due to CBD.

battery (word presentation, working memory and word recognition tasks), EEG
recording.
Wade et al.

Multiple Sclerosis

2004 [81]

Guy et al.

Journal of Cannabis

2003 [82]

Therapeutics

Scopus,

Multi-center, double-blind,

Intervention with CMBE: ∆9-THC+CBD (ratio of 1:1, 2.5 – 120mg, daily) in

No groups to control for ∆9-THC or

Web of

randomised, placebo-

MS outpatients (n=160). Recorded VAS of symptoms, disability, mood,

CBD effects alone (only Sativex vs.

Science,

controlled, parallel group

cognition, sleep and fatigue.

placebo).

Medline

trial

Scopus

Partially randomised,

Intervention with whole-plant extracts of ∆9-THC, CBD, ∆9-THC: CBD (1:1

No behavioural tests were performed

placebo-controlled, cross-

ratio) and placebo to assess tolerability of sublingual drops, sublingual aerosol

to assess cognition.

over trial

or inhalation delivery methods to healthy subjects (n=6). Assessed
pharmacokinetics and self-reported symptoms, well-being, intoxication scores,
mood and cognition, and adverse event scores.

Leweke et al.

Pharmacology Biochemistry

Scopus,

Double-blind, crossover

Intervention with nabilone (1 mg) and CBD (200 mg) on binocular depth

No behavioural tests were performed

2000 [83]

and Behaviour

Medline

trial

inversion in male human volunteers (n=9). Assessed subjective measures of

to assess cognition.

mood, anxiety and vividness of imagery.
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